



**BRIDGEPORT HOSPITAL
RADIATION SAFETY OFFICE**

NRC License No.: 06-01060-01

Docket No.: 030-01247

June 16, 2015

U.S. Nuclear Regulatory Commission, Region I
2100 Renaissance Boulevard, Suite 100
King of Prussia, PA 19406-2713

03001247
Br. 1

**RE: Bridgeport Hospital Amendment Request to Add a New Authorized User to
License No.: 06-01060-01.**

Gentlemen & Women of the NRC:

Bridgeport Hospital would like to amend its license to add Adam Kaye, M.D. as an Authorized User for Uptake, Dilution and Excretion studies (10 CFR 35.100), Imaging and Localization studies (10 CFR 35.200) and for the use of byproduct materials where a written directive is required for < 33 mCi of Sodium Iodide I-131, > 33 mCi of Sodium Iodide I-131 and Parenteral Administration of any beta emitter, or photon-emitting radionuclide with a photon energy less than 150 keV (10 CFR 35.300).

Attached to this letter you will find a letter from the University of Pennsylvania attesting to Dr. Kaye's status as an Authorized user on the State of Pennsylvania Broad Scope License #PA-0131.

If you have any further questions, please feel free to contact Mr. Bohan at (203) 688-2950, or mike.bohan@yale.edu.

Regards,

Michael R. Tatta
Director, Imaging, Laboratory & Radiation Oncology

Attachments: UPenn letter signed by Eileen Normoyle, RSO

267 Grant Street
Bridgeport, CT 06110

REC'D IN LAT 6-18-15

588254
NMSS/RGN1 MATERIALS-002

UNIVERSITY of PENNSYLVANIA

Environmental Health & Radiation Safety

3160 Chestnut Street, Suite 400

Philadelphia, PA 19104-6287

Tel: (215) 898-4453

Fax: (215) 898-0140


June 12, 2015

Dr. Adam Kaye,

This letter is to notify you that on June 5, 2014 you were approved as an Authorized User at the University of Pennsylvania (State of Pennsylvania Broad Scope License # PA-0131) for the following types of radioactive materials uses:

- Uptake, Dilution, and Excretion studies for which a written directive is not required (10 CFR 35.100)
- Imaging and Localization studies for which a written directive is not required (10 CFR 35.200)
- Byproduct material for which a written directive is required (10 CFR 35.300) for the following categories:
 - Oral administration of less than or equal to 1.22 GBq (33 mCi) of sodium iodide I-131
 - Oral administration of greater than 1.22 GBq (33 mCi) of sodium iodide I-131
 - Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV.

Sincerely,



Eileen Normoyle

Radiation Safety Officer/Director of Radiation Safety

Environmental Health and Radiation Safety

University of Pennsylvania

This is to acknowledge the receipt of your letter application dated

6-16-15, and to inform you that the initial processing which includes an administrative review has been performed.

☒ Amend: 06-01060-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 588254.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.